目的 探讨急性脑梗死患者治疗前后血清白细胞介素（IL-18）和血浆溶血磷脂酸（LpA）、D-二聚体（D-D）水平的变化及临床意义。方法 对38例急性脑梗死患者应用双抗体夹心酶联免疫吸附法（ELISA）检测血清IL-18、D-D，生化法检测血浆LpA 并与35名正常人作比较。结果 治疗前患者IL-18平均水平为872.4±318.6pg/mL、LpA为3.5±0.85μmmol/L、D-D为602.4±84.5 ng/mL，与正常人相比差异具有统计学意义（P＜0.01）；经治疗2周后患者IL-18平均水平为412.5±114.6pg/mL、LpA为2.3±0.90μmmol/L、D-D为218.6±55.4 ng/mL，与正常人比较差异无统计学意义（P＞0.05）。结论 检测急性脑梗死患者治疗前后血清IL-18和血浆LpA、D-D水平的变化有助于对治疗效果和预后的判断。

Objective To explore clinical significance of changes of serum levels of Interleukin-18 (IL-18) and plasma lysophosphatidic acid (LpA) before and after treatment in patients with acute cerebral infarction. Methods The levels of IL-18, LpA and D-dimer (D-D) in 38 cases of acute cerebral infarction before and after treatment, and 35 healthy controls were detected by using ELISA, biochemistry. Results The average levels of IL-18, LpA and D-D in patients with acute cerebral infarction before treatment were significantly higher than those in controls (P＜0.01). There were no significant difference on the average levels of IL-18, LpA and D-D between patients after 2 weeks treatment and controls (P＞0.05). Conclusion The detection of changes of serum IL-18, plasma LpA and D-D Levels before and after treatment in patients with acute cerebral infarction might be helpful to monitor the theraputic efficacy and prognosis.